Carmike Cinemas Earnings: Deep Analysis for Investors
The following is an excerpt from a report compiled by Michael Pachter of Wedbush Securities.
Q3 revenue was in-line with our estimate, but costs were higher than recent trends. Despite managing film rental and concession costs in line with our estimates, Carmike’s (NASDAQ:CKEC) other theater operating costs and G&A rose well above our expectations, triggering EPS of $0.13 vs. our $0.24 estimate. We believe that as it grows its footprint, Carmike will be able to leverage its G&A, and will gain negotiating leverage with the studios to drive film rental costs even lower. For the next fiscal year, we anticipate a higher run-rate for other theater operating costs and G&A.
Adjusting our forward estimates to reflect a higher cost structure. We are maintaining our FY:12 estimate for revenue of $524 million, but are decreasing our estimates for Adjusted EBITDA to $87 million from $91 million and for EPS to $0.87from $1.23 to reflect a higher cost structure as the company adds screens. Our FY:13 Adjusted EBITDA goes to $110 million from $115 million.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Carmike will acquire 251 screens in Q4. Including capital leases, debt from the acquisitions grows by ≈ $100 million and the company will spend $19 million in cash for the 16 theaters, raising enterprise value by $120 million. We expect no additional capital expenditures, and expect synergies to positively impact financials in 2013. After adjustments, we expect 2013 adjusted EBITDA of $110 million.
Q4 quarter-to-date box office is tracking up over 20%, with all major Q4 blockbusters still upcoming. Taken 2 led October, and we expect the Twilight finale to lead November and The Hobbit to lead December releases. We recall that in Q4:11 the release slate was crowded with single-genre weekends, and overall box office receipts suffered as a result. We do not view this as a risk to Q4:12 given a variety of blockbusters within all genres as well as more favorable timing of the release slate compared to last year. As a result, we view our Q4 box office estimate of up 6.2% as conservative.
Reiterating our OUTPERFORM rating, but lowering our price target to $19 from $21. Our price target reflects a 5.2x EV/EBITDA multiple applied to our 2013 estimate, well below its peers and below its historical multiple of 5.9x given some volatility during its turnaround, plus ≈ 7x applied to $3 million in incremental accounting profit we project in 2013 from Screenvision (adding $1 to its PT). We believe there is upside to our price target given the potential for substantial earnings upside should revenue surpass expectations.
Michael Pachter is an analyst at Wedbush Securities.
Don’t Miss: Is Hulu Edging in on Netflix?